Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
Prostate cancer is the most common cancer in men in Western countries, with a high incidence of bone metastasis. Ganoderic acid DM, with 5alpha-reductase inhibitory and androgen receptor (AR) binding activity, isolated from the ethanol extracts of Ganoderma lucidum, can inhibit prostate cancer cell growth and block osteoclastogenesis.
Liu
Jie
J
Department of Forest and Forest Products Science, Faculty of Agriculture, Kyushu University, Fukuoka, Japan.
Shiono
Jun
J
Shimizu
Kuniyoshi
K
Kukita
Akiko
A
Kukita
Toshio
T
Kondo
Ryuichiro
R
D000726:Androgen Antagonists / Q000737:chemistry* / Q000302:isolation & purification / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D006131:Growth Inhibitors / Q000737:chemistry* / Q000302:isolation & purification / Q000494:pharmacology; D006801:Humans; D008297:Male; D051379:Mice; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D020940:Reishi; D014315:Triterpenes / Q000737:chemistry* / Q000302:isolation & purification / Q000494:pharmacology
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D014315:Triterpenes; C528901:ganoderic acid D